Our top pick for
Building a portfolio
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Purple Innovation Inc is a furnishings, fixtures & appliances business based in the US. Purple Innovation shares (PRPL) are listed on the NASDAQ and all prices are listed in US Dollars. Purple Innovation employs 1,600 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$22.53|
|52-week range||$21.69 - $40.81|
|50-day moving average||$24.54|
|200-day moving average||$28.50|
|Wall St. target price||$36.80|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-2.56|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-09-17)||-0.18%|
|1 month (2021-08-26)||-9.92%|
|3 months (2021-06-25)||-19.39%|
|6 months (2021-03-26)||-26.59%|
|1 year (2020-09-25)||-7.93%|
|2 years (2019-09-26)||190.71%|
|3 years (2018-09-26)||297.35%|
|5 years (2016-09-26)||129.90%|
Valuing Purple Innovation stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Purple Innovation's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Purple Innovation's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.2676. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Purple Innovation's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Purple Innovation's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $53.8 million.
The EBITDA is a measure of a Purple Innovation's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$730 million|
|Operating margin TTM||6.32%|
|Gross profit TTM||$305.1 million|
|Return on assets TTM||6.53%|
|Return on equity TTM||-153.26%|
|Market capitalisation||$1.5 billion|
TTM: trailing 12 months
There are currently 4.9 million Purple Innovation shares held short by investors – that's known as Purple Innovation's "short interest". This figure is 6% up from 4.6 million last month.
There are a few different ways that this level of interest in shorting Purple Innovation shares can be evaluated.
Purple Innovation's "short interest ratio" (SIR) is the quantity of Purple Innovation shares currently shorted divided by the average quantity of Purple Innovation shares traded daily (recently around 719507.07964602). Purple Innovation's SIR currently stands at 6.78. In other words for every 100,000 Purple Innovation shares traded daily on the market, roughly 6780 shares are currently held short.
However Purple Innovation's short interest can also be evaluated against the total number of Purple Innovation shares, or, against the total number of tradable Purple Innovation shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Purple Innovation's short interest could be expressed as 0.07% of the outstanding shares (for every 100,000 Purple Innovation shares in existence, roughly 70 shares are currently held short) or 0.0844% of the tradable shares (for every 100,000 tradable Purple Innovation shares, roughly 84 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Purple Innovation.
Find out more about how you can short Purple Innovation stock.
We're not expecting Purple Innovation to pay a dividend over the next 12 months.
Over the last 12 months, Purple Innovation's shares have ranged in value from as little as $21.69 up to $40.81. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Purple Innovation's is 1.4002. This would suggest that Purple Innovation's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Purple Innovation, Inc. designs and manufactures mattresses, pillows, and cushions. It also offers sheets, mattress protectors, bed frames, seat cushions, and weighted blankets and duvets. The company markets and sells its products through direct-to-consumer online channels, retail brick-and-mortar wholesale partners, and third-party online retailers, as well as through its factory outlet and the company owned showrooms. Purple Innovation, Inc. was founded in 2010 and is headquartered in Lehi, Utah. .
Everything we know about the Enfusion IPO, plus information on how to buy in.
Everything we know about the Intuity Medical IPO, plus information on how to buy in.
Everything we know about the Pyxis Oncology IPO, plus information on how to buy in.
Everything we know about the AEON Biopharma IPO, plus information on how to buy in.
Everything we know about the IHS Holding Ltd IPO, plus information on how to buy in.
Everything we know about the BT Brands IPO, plus information on how to buy in.
Everything we know about the Immix IPO, plus information on how to buy in.
Everything we know about the Keter Group SA IPO, plus information on how to buy in.
Everything we know about the Theseus Pharmaceuticals IPO, plus information on how to buy in.
Everything we know about the MiNK Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.